News on Viral Hepatitis in HIV: Update from the 2016 GEHEP Conference.
The II Conference of the Group for the Study of Viral Hepatitis (GEHEP) (29 September-1 October, Spain) updated epidemiological, diagnostic and treatment aspects on viral hepatitis. The conference was mostly focused on the latest news related to HCV infection, including the successes achieved since the implementation of direct-acting antiviral agents for HCV therapy, but also in the new, future challenges for a real HCV eradication. The scenario for chronic HCV infection has dramatically changed in the last two years and most patients have been cured after 12 weeks of therapy with minimal side effects. However, as the experience of treatment increases, new challenges have emerged for the maximum optimization and success of therapy. Moreover, different issues need to be resolved for a real HCV eradication (i.e. unmasking HCV infection, prevention and diagnosis of HCV reinfections, diagnostic tools for treatment optimization). The latest advances in the knowledge on these topics were presented and discussed at this conference. Also, some interesting studies related to viral hepatitis E were addressed. This review summarizes some of the major findings reported and discussed during the GEHEP Conference.
Division of Clinical Virology, Instituto de Investigación Biomédica de A Coruña (INIBIC)-Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade da Coruña (UDC), Spain.
Eva
E
Poveda
Azienda Ospedaliera Ospedale Niguarda Ca'Granda, Milan, Italy.
Massimo
M
Puoti
Consorcio General Hospital, Universitario de Valencia, Valencia, Spain.
Miguel
M
García-Deltoro
Unit of Infectious Diseases and Microbiology, Hospital Universitario de Valme, Seville, Spain.
Juan A
JA
Pineda
Unit of Infectious Diseases and Microbiology, Hospital Universitario Puerto Real, Cádiz, Spain.
Francisco
F
Téllez
Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain.
Rafael
R
Granados
Unit of Infectious Diseases, University Hospital Álvaro Cunqueiro, Vigo, Spain.
Luis
L
Morano
Department of Microbiology, Instituto de Investigación Biosanitaria (IBS)-Complejo Hospitalario Universitario de Granada, Granada, Spain.
Federico
F
García
D000998:Antiviral Agents / Q000627:therapeutic use; D024882:Drug Resistance, Viral; D015658:HIV Infections / Q000150:complications*; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology; D016751:Hepatitis E / Q000188:drug therapy; D006801:Humans
D000998:Antiviral Agents